{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T10:08:42Z","timestamp":1750154922798},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s10620-009-0769-5","type":"journal-article","created":{"date-parts":[[2009,3,6]],"date-time":"2009-03-06T16:43:28Z","timestamp":1236357808000},"page":"1693-1701","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Efficacy of Lansoprazole in Preventing Relapse of Erosive Reflux Esophagitis"],"prefix":"10.1007","volume":"54","author":[{"given":"Thomas O.","family":"Kovacs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Freston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian M.","family":"Haber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Peura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,7]]},"reference":[{"issue":"Suppl. B","key":"769_CR1","first-page":"13","volume":"41","author":"G Holtmann","year":"2005","unstructured":"Holtmann G. Understanding GERD symptoms in the clinical setting. Drugs Today (Barc). 2005;41(Suppl. B):13\u201317. doi: 10.1358\/dot.2005.41.1.875775 . Barc.","journal-title":"Drugs Today (Barc)"},{"issue":"Suppl. 8","key":"769_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2036.2004.02224.x","volume":"20","author":"G Holtmann","year":"2004","unstructured":"Holtmann G, Adam B, Liebregts T. Review article: the patient with gastro-esophageal reflux disease\u2013\u2013lifestyle advice and medication. Aliment Pharmacol Ther. 2004;20(Suppl. 8):24\u201327. doi: 10.1111\/j.1365-2036.2004.02224.x .","journal-title":"Aliment Pharmacol Ther"},{"key":"769_CR3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01720610-200512000-00003","volume":"18","author":"EA Featherstone","year":"2005","unstructured":"Featherstone EA. Severe GERD: effective treatment prevents potentially serious complications. JAAPA. 2005;18:25\u201329.","journal-title":"JAAPA"},{"issue":"Suppl. 5","key":"769_CR4","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.3949\/ccjm.70.Suppl_5.S33","volume":"70","author":"MB Fennerty","year":"2003","unstructured":"Fennerty MB. The continuum of GERD complications. Cleve Clin J Med. 2003;70(Suppl. 5):S33\u2013S50.","journal-title":"Cleve Clin J Med"},{"key":"769_CR5","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2165\/00003495-200262080-00004","volume":"62","author":"JW Freston","year":"2002","unstructured":"Freston JW, Jackson RL, Huang B, Ballard ED. Lansoprazole for maintenance of remission of erosive esophagitis. Drugs. 2002;62:1173\u20131184. doi: 10.2165\/00003495-200262080-00004 .","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"769_CR6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000200911","volume":"51","author":"SJ Spechler","year":"1992","unstructured":"Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion. 1992;51(Suppl. 1):24\u201329.","journal-title":"Digestion"},{"issue":"Suppl. 8","key":"769_CR7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.2004.02223.x","volume":"20","author":"Y Kinoshita","year":"2004","unstructured":"Kinoshita Y. Review article: treatment for gastro-esophageal reflux disease\u2013\u2013lifestyle advice and medication. Aliment Pharmacol Ther. 2004;20(Suppl. 8):19\u201323. doi: 10.1111\/j.1365-2036.2004.02223.x .","journal-title":"Aliment Pharmacol Ther"},{"key":"769_CR8","doi-asserted-by":"crossref","unstructured":"Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005;CD003245.","DOI":"10.1002\/14651858.CD003245.pub2"},{"key":"769_CR9","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1007\/BF02071390","volume":"41","author":"SD Mathias","year":"1996","unstructured":"Mathias SD, Castell DO, Elkin EP, Matosian ML. Health-related quality of life of patients with acute erosive reflux esophagitis. Dig Dis Sci. 1996;41:2123\u20132129. doi: 10.1007\/BF02071390 .","journal-title":"Dig Dis Sci"},{"key":"769_CR10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/00042737-199611000-00013","volume":"8","author":"CJ Mulder","year":"1996","unstructured":"Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30\u00a0mg versus omeprazole 40\u00a0mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group. Eur J Gastroenterol Hepatol. 1996;8:1101\u20131106. doi: 10.1097\/00042737-199611000-00013 .","journal-title":"Dutch Study Group. Eur J Gastroenterol Hepatol"},{"key":"769_CR11","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1111\/j.1572-0241.2001.05263.x","volume":"96","author":"JE Richter","year":"2001","unstructured":"Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencyla JL. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol. 2001;96:3089\u20133098. doi: 10.1111\/j.1572-0241.2001.05263.x .","journal-title":"Am J Gastroenterol"},{"key":"769_CR12","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0016-5085(88)90162-X","volume":"95","author":"DJ Hetzel","year":"1988","unstructured":"Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903\u2013912.","journal-title":"Gastroenterology"},{"key":"769_CR13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2036.2005.02643.x","volume":"22","author":"J Labenz","year":"2005","unstructured":"Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20\u00a0mg vs. pantoprazole 20\u00a0mg for maintenance therapy of healed erosive esophagitis: results from the EXPO study. Aliment Pharmacol Ther. 2005;22:803\u2013811. doi: 10.1111\/j.1365-2036.2005.02643.x .","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 1","key":"769_CR14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2036.17.s1.7.x","volume":"17","author":"K Lauritsen","year":"2003","unstructured":"Lauritsen K, Devi\u00e8re J, Bigard MA, et al. Esomeprazole 20\u00a0mg and lansoprazole 15\u00a0mg in maintaining healed reflux esophagitis: metropole study results. Aliment Pharmacol Ther. 2003;17(Suppl. 1):24\u201327. doi: 10.1046\/j.1365-2036.17.s1.7.x .","journal-title":"Aliment Pharmacol Ther"},{"key":"769_CR15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.7326\/0003-4819-124-10-199605150-00001","volume":"124","author":"M Robinson","year":"1996","unstructured":"Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;124:859\u2013867.","journal-title":"Ann Intern Med"},{"key":"769_CR16","first-page":"1758","volume":"91","author":"SJ Sontag","year":"1996","unstructured":"Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Haber M. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The lansoprazole maintenance study group. Am J Gastroenterol. 1996;91:1758\u20131765.","journal-title":"Am J Gastroenterol"},{"key":"769_CR17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1023\/A:1005548318996","volume":"45","author":"B Thjodleifsson","year":"2000","unstructured":"Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. Dig Dis Sci. 2000;45:745\u2013753. doi: 10.1023\/A:1005548318996 .","journal-title":"Dig Dis Sci"},{"issue":"Suppl. 2","key":"769_CR18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2036.2001.00115.x","volume":"15","author":"GN Tytgat","year":"2001","unstructured":"Tytgat GN. Review article: long-term use of proton pump inhibitors in GERD\u2013\u2013help or hindrance? Aliment Pharmacol Ther. 2001;15(Suppl. 2):6\u20139. doi: 10.1046\/j.1365-2036.2001.00115.x .","journal-title":"Aliment Pharmacol Ther"},{"key":"769_CR19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1572-0241.2002.05666.x","volume":"97","author":"F Baldi","year":"2002","unstructured":"Baldi F, Morselli-Labate AM, Cappiello R, Ghersi S. Italian lansoprazole study group: daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Am J Gastroenterol. 2002;97:1357\u20131364. doi: 10.1111\/j.1572-0241.2002.05666.x .","journal-title":"Am J Gastroenterol"},{"issue":"(Suppl. 3)","key":"769_CR20","first-page":"182","volume":"39","author":"L Carling","year":"1996","unstructured":"Carling L, Axelsson C, Forsell H, et al. Lansoprazole versus omeprazole in long term maintenance treatment of refluxoesophagitis: a Scandinavian multicentre trial. Gut. 1996;39((Suppl. 3)):182. Abstract.","journal-title":"Gut"},{"key":"769_CR21","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1046\/j.1365-2036.2001.01105.x","volume":"15","author":"K Geboes","year":"2001","unstructured":"Geboes K, Dekker W, Mulder CJ, Nusteling K. Dutch study group: long-term lansoprazole treatment for gastro-esophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther. 2001;15:1819\u20131826. doi: 10.1046\/j.1365-2036.2001.01105.x .","journal-title":"Aliment Pharmacol Ther"},{"key":"769_CR22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2036.1997.144320000.x","volume":"11","author":"JG Hatlebakk","year":"1997","unstructured":"Hatlebakk JG, Berstad A. Lansoprazole 15 and 30\u00a0mg daily in maintaining healing and symptom relief in patients with reflux esophagitis. Aliment Pharmacol Ther. 1997;11:365\u2013372. doi: 10.1046\/j.1365-2036.1997.144320000.x .","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl","key":"769_CR23","doi-asserted-by":"crossref","first-page":"A195","DOI":"10.1016\/0016-5085(95)23441-1","volume":"108","author":"T Poynard","year":"1995","unstructured":"Poynard T, Staub JL, Lemerez M, Deltenre M, Rekacevicz C, Sallerin V. Efficacy and safety of lansoprazole 15\u00a0mg OAD or 30\u00a0mg OAD as one year maintenance treatment for erosive reflux esophagitis: a randomized trial. Gastroenterology. 1995;108(Suppl):A195. doi: 10.1016\/0016-5085(95)23441-1 . Abstract.","journal-title":"Gastroenterology"},{"key":"769_CR24","unstructured":"Ip S, Bonis P, Tatsioni A, Raman G, Chew P, Kupelnick B, et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. Evidence Report\/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. December 2005. Available at: http:\/\/effectivehealthcare.ahrq.gov\/repFiles\/GERD%20Final%20Report.pdf . Accessed 25 April 2007."},{"key":"769_CR25","first-page":"211","volume":"72","author":"EJ Kuipers","year":"1999","unstructured":"Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SG. Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease. Yale J Biol Med. 1999;72:211\u2013218.","journal-title":"Yale J Biol Med"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-009-0769-5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T13:53:20Z","timestamp":1558187600000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-009-0769-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,7]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["769"],"URL":"https:\/\/doi.org\/10.1007\/s10620-009-0769-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,7]]}}}